Fortress Biotech Files 8-K
Ticker: FBIOP · Form: 8-K · Filed: Jan 6, 2025 · CIK: 1429260
| Field | Detail |
|---|---|
| Company | Fortress Biotech, INC. (FBIOP) |
| Form Type | 8-K |
| Filed Date | Jan 6, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $129 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing, company-update
Related Tickers: FBIO
TL;DR
FBIO filed an 8-K on Jan 6, 2025, but details are scarce. Need more info.
AI Summary
Fortress Biotech, Inc. filed an 8-K on January 6, 2025, reporting an "Other Event." The filing does not contain specific details about the event, dollar amounts, or definitive dates beyond the filing date itself. The company is incorporated in Delaware and its principal executive offices are located in Bay Harbor Islands, Florida.
Why It Matters
This filing indicates a material event has occurred for Fortress Biotech, Inc., requiring disclosure to investors. However, the lack of specific details necessitates further investigation to understand the event's implications.
Risk Assessment
Risk Level: medium — The filing is an 8-K, indicating a significant event, but the lack of specific details in the provided text creates uncertainty about the nature and impact of the event.
Key Players & Entities
- Fortress Biotech, Inc. (company) — Registrant
- January 6, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Bay Harbor Islands, FL (location) — Address of Principal Executive Offices
- CORONADO BIOSCIENCES INC (company) — Former Company Name
FAQ
What specific event is Fortress Biotech, Inc. reporting in this 8-K filing?
The provided text of the 8-K filing does not specify the nature of the 'Other Event' being reported, only that it occurred on or before January 6, 2025.
What is the significance of the 'Other Events' item information in this filing?
The 'Other Events' item information signifies that a material event has occurred that the company is required to disclose to the SEC, but the specific details are not elaborated upon in the provided excerpt.
When was Fortress Biotech, Inc. incorporated, and where are its principal executive offices located?
Fortress Biotech, Inc. was incorporated in Delaware, and its principal executive offices are located at 1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL 33154.
Has Fortress Biotech, Inc. undergone any previous name changes?
Yes, Fortress Biotech, Inc. was formerly known as CORONADO BIOSCIENCES INC, with a date of name change on March 10, 2008.
What is the SEC file number and film number associated with this 8-K filing?
The SEC file number for this filing is 001-35366, and the film number is 25509100.
Filing Stats: 498 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2025-01-06 08:05:15
Key Financial Figures
- $129 million — eligible to receive royalties and up to $129 million in aggregate development and sales mile
Filing Documents
- fbio-20250106x8k.htm (8-K) — 39KB
- 0001558370-25-000025.txt ( ) — 192KB
- fbio-20250106.xsd (EX-101.SCH) — 4KB
- fbio-20250106_def.xml (EX-101.DEF) — 15KB
- fbio-20250106_lab.xml (EX-101.LAB) — 17KB
- fbio-20250106_pre.xml (EX-101.PRE) — 15KB
- fbio-20250106x8k_htm.xml (XML) — 7KB
01. Other Events
Item 8.01. Other Events . On January 6, 2025, Cyprium Therapeutics, Inc. (" Cyprium "), a majority-owned subsidiary of Fortress Biotech, Inc. (the " Company " or " Fortress "), announced that the U.S. Food and Drug Administration (the " FDA ") accepted the New Drug Application (" NDA ") for CUTX-101 (Copper Histidinate) for priority review with a target action date of June 30, 2025. In December 2023, Sentynl Therapeutics, Inc. (" Sentynl "), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd. (" Zydus Group "), assumed full responsibility for the development and commercialization of CUTX-101 from Cyprium. The NDA submission was completed by Sentynl who will be responsible for commercialization upon approval. Cyprium will retain ownership over any Priority Review Voucher that may be issued at NDA approval and is eligible to receive royalties and up to $129 million in aggregate development and sales milestones. Fortress founded Cyprium in 2017 and currently owns approximately 76% of Cyprium. 99
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Fortress Biotech, Inc. (Registrant) Date: January 6, 2025 By: /s/ David Jin David Jin Chief Financial Officer